Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
Shareholders in Bio-Rad Laboratories (NYSE:BIO) Are in the Red If They Invested Three Years Ago
What You Need to Know Ahead of Bio-Rad Laboratories' Earnings Release
Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
Express News | NYSE Halt Bio-Rad Labs B Add Info Lst $283.450400
Incyte, Moderna Among Most Shorted S&P 500 Healthcare Stocks in June
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
S&P 500 Ends First Half Shy Of All-Time Highs. Here Are The Leaders And Laggards — And 5 Stocks That Could Outperform In Next 6 Months
RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Express News | Bio Rad Laboratories Inc : RBC Cuts Target Price to $402 From $414
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Bio-Rad Laboratories on Pace for Largest Percent Increase Since December 2023 -- Data Talk
$842.7 Million SDS Poly Acrylamide Gel Electrophoresis Market Forecast, 2030 - Featuring Profiles of 13 Companies Including Abcam, Bio-Rad Laboratories, GE Healthcare, and Thermo Fisher Scientific
There's Reason For Concern Over Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Price
Bio-Rad Laboratories(BIO.US) Officer Sells US$104.02K in Common Stock
Is Bio-Rad Laboratories (BIO) a Lucrative Investment?
Form 144 | Bio-Rad Laboratories(BIO.US) Officer Proposes to Sell 104.02K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael intends to sell 369 shares of its common stock on Jun 13, with a total market value of approximately $104.02K.
Citi Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Cuts Target Price to $300
Bio-Rad Laboratories Coverage Assumed by Jefferies at Hold Vs Previous Rating of Buy
Express News | Jefferies Assumes Bio-Rad Laboratories at Hold, Lowers Price Target of $315